The AACR Cancer Progress Report 2022 was officially released during a policy briefing on Wednesday, September 21. This report hightlights research-driven advances against the collection of devastating diseases we call cancer.
A NEW FRONTIER: THE VERY EARLY DETECTION OF CANCER SIGNALS
Registration is free for this virtual forum that will highlight the latest research in cancer’s very early detection, as well as discuss the benefits and potential negatives of these new cancer screening tests.
This virtual forum explored how biomarkers are changing cancer research and care to benefit patients with cancer. The recording is now available for on-demand viewing
From funding research grants to minimizing the barriers to clinical trials, the decisions made in Washington, D.C., directly influence the rate of progress in the war against cancer. Issues regarding health and science are becoming increasingly complex, and competition for limited resources is steadily increasing. These times require that cancer researchers become more actively involved in the policy-making process and take time to educate the public about the exciting progress occurring in the fight against cancer.
The AACR’s principal means for devising and implementing strategies to influence funding and important biomedical research-related public policy issues through The Science Policy and Government Affairs Committee and its subcommittees:
Science Policy and Government Affairs Committee. Provides guidance on public issues of concern to cancer researchers and focuses on mechanisms for speeding up cancer research.
- Regulatory Science and Policy Subcommittee. Supports the efforts of the FDA to modernize the regulatory process and accommodate the fast pace of innovation in science and technology.
- Tobacco Products and Cancer Subcommittee. Fosters scientific and policy initiatives to reduce the incidence of disease and mortality due to tobacco use.
- Health and Policy Subcommittee. Develops and promotes policies and member education initiatives that will foster the closer integration of clinical practice and cancer research.